Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Blood Adv. 2020 Apr 14;4(7):1501-1511. doi: 10.1182/bloodadvances.2019001378.
Sickle cell nephropathy results in chronic kidney disease (CKD), which is associated with significant morbidity and mortality in sickle cell anemia (SCA). Albuminuria is an early manifestation of sickle nephropathy; however, little is known about progression of albuminuria or its correlation with glomerular filtration rate (GFR) decline or CKD. We studied nephropathy progression in 303 SCA participants in a prospective, multicenter, longitudinal study. We collected steady-state urine and serum samples yearly and assessed albumin/creatinine ratio (ACR), estimated GFR (eGFR), and SCA and nephropathy biomarkers. Participants with albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements were classified as having persistent albuminuria (PA). At baseline (mean age, 21 years; range, 2-64 years), 32% had albuminuria. In longitudinal multivariate analysis, ACR was associated with sex, anemia, older age, and higher bilirubin and kidney injury molecule-1 levels. Albuminuria increased with age by 3.5 mg/g per year (P < .0001). Of 175 participants with ≥3 annual samples, 81% with baseline albuminuria ≥100 mg/g developed PA. Decreased eGFR and adult CKD were associated with PA (P = .002 and P = .02, respectively), but not with baseline albuminuria. Rate of eGFR decline was steeper among adults (but not children) with albuminuria, compared with those without (P = .02). Participants with PA were more likely to have rapid eGFR decline compared with those without (P = .03). In this longitudinal study, albuminuria progressed with age, and adults with albuminuria had worse eGFR decline than those without. Albuminuria ≥100 mg/g predicted PA, which was associated with rapid eGFR decline and CKD development in adults with SCA. This trial was registered at www.clinicaltrials.gov as #NCT02239016.
镰状细胞肾病导致慢性肾脏病(CKD),这与镰状细胞贫血症(SCA)患者的高发病率和死亡率密切相关。蛋白尿是镰状肾病的早期表现;然而,对于蛋白尿的进展或其与肾小球滤过率(GFR)下降或 CKD 的相关性知之甚少。我们对 303 名镰状细胞贫血症患者进行了一项前瞻性、多中心、纵向研究,以研究肾病的进展情况。我们每年收集稳定的尿液和血清样本,并评估白蛋白/肌酐比值(ACR)、估计肾小球滤过率(eGFR)以及镰状细胞贫血症和肾病生物标志物。如果患者的蛋白尿(ACR≥30mg/g)连续两年以上,则被归类为持续性蛋白尿(PA)。在基线时(平均年龄为 21 岁,范围为 2-64 岁),32%的患者存在蛋白尿。在纵向多变量分析中,ACR 与性别、贫血、年龄较大以及胆红素和肾损伤分子-1 水平较高有关。白蛋白尿每年增加 3.5mg/g(P<0.0001)。在 175 名具有≥3 个年度样本的患者中,基线白蛋白尿≥100mg/g 的患者中 81%发展为 PA。eGFR 下降和成人 CKD 与 PA 相关(P=0.002 和 P=0.02),但与基线白蛋白尿无关。与无蛋白尿的患者相比,有蛋白尿的成年人的 eGFR 下降速度更快(P=0.02)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。有蛋白尿的患者与无蛋白尿的患者相比,eGFR 下降速度更快(P=0.03)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。有蛋白尿的患者与无蛋白尿的患者相比,eGFR 下降速度更快(P=0.03)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。该试验在 www.clinicaltrials.gov 上注册为 #NCT02239016。